Bassel Nazha, MD, MPH retweeted
IT IS THIS TIME OF THE YEAR AGAIN!
TOP 10 GU clinical trials in 2025!
1/ Practice-changing IMvigor011: In ctDNA+ MIBC post-cystectomy, adjuvant atezo improved DFS (HR 0.64) & OS (HR 0.59) vs placebo. ctDNA- pts spared therapy w/ 2-yr DFS ~88%.
@tompowles1 @DrYukselUrun @OncoBellmunt @NEJM #ESMO2025 Plenary @myESMO
nejm.org/doi/full/10.1056/NE…
Bassel Nazha, MD, MPH retweeted
Day ONE of #PROSCA25
#GlobalForum25 in Portugal 🇵🇹
Presentation by Julien Van Damme 🇧🇪 during the Unfavourable intermediate- and high-risk PCa Session
Presenting: PSA-only monitoring in BCR: Who qualifies?
PSA-only biochemical recurrence represents a highly heterogeneous disease state, but clinicians can generally distinguish between two main groups: patients with slow PSA kinetics, low PSA levels, and intermediate-grade disease, who are appropriate for surveillance or local salvage approaches, and patients with rapid PSA kinetics, high PSA levels, and high-grade disease, who require prompt, intensive systemic therapy such as ARPI plus ADT for at least nine months. Additionally, monitoring PSA response helps identify which patients may safely undergo intermittent therapy, reducing treatment burden, stress, and side effects. #ProstateCancer
@mdesantis234
@FontesMario
@fontev1
@Silke_Gillessen
@karolien_goffin
@PGrivasMDPhD
@bkonety
@Uro_Kris
@Dolmos77
@AOmlin
@HenningPlage
@DanieleRaggi83
@Tilki_De
@BertrandTOMBAL
@vandamme_jvd
@roodvdb
@UrsulaVogl
@ZilliThomas
@nataliagandur
@DrRishabhOnco
@mirrorsmed
Bassel Nazha, MD, MPH retweeted
Day 2 #ESMO25 Highlights:
Breast Ca:
1. #DESTINYBreast11 NeoAdj TDXd
2. #DESTINYBreast05: TDXd in residual disease
3. #evERA: Giredestrant HR+
4. #VIKTORIA1: Gedatolisib HR+
GU:
5. #KEYNOTE905: PeriOp EV + Pembro MIBC
@myESMO #OncTwitter @OncoAlert @OncUpdates
1/13
Bassel Nazha, MD, MPH retweeted
🩺🎓 Training teaches the medicine, but not always the whole picture.
💡If you're starting your first attending job, you may find our article with @IvyLorena_Md on aspects of oncology that aren't taught in training helpful.
👉connection.asco.org/do/eight…
#ASCOconnection @ASCO
Bassel Nazha, MD, MPH retweeted
1/5 People living with sickle-cell disease (SCD) face ↑ cancer risk, including #RenalMedullaryCarcinoma. Our latest @ImmunityCP study suggests a culprit is the reshaping CD8⁺ T cell chromatin by SCD 👉authors.elsevier.com/sd/arti… #MsaouelLab
Bassel Nazha, MD, MPH retweeted
The final talk of #AtlantaGU25 👋! @virajmaster and @BasselNazha from @WinshipAtEmory join together with @DocMattCampbell from @MDAndersonNews and @shaib_walid from Northwest Georgia Oncology Centers to discuss #raretumors 🔍 in #GUoncology. Session Chair: @VikramNarayan from @WinshipAtEmory. 🌟Join us next time! Visit education.binayfoundation.or… for more upcoming CME conferences! #MedTwitter #MedX #MedEd
Bassel Nazha, MD, MPH retweeted
Expanding the application of PSMA therapy #GU25
Exciting new data on the horizon. Trials on trials on trial… and even more to come. Check out mechanisms to optimize PSMA theranostics
🔎Work needed on mechanism/resistance in PSMA neg disease
🔎We need to understanding tumor microenvironment
🔎Role of alpha emitters? Combination w/ beta emitters?
@ASCO @OncoAlert @GUOncologyNow @urotoday @TargetedOnc @OncoReporte
Bassel Nazha, MD, MPH retweeted
We had a great night to focus on GU oncology with colleagues across the town @OncLive @OncLiveSOSS @WinshipAtEmory
Bassel Nazha, MD, MPH retweeted
Northwell heme/onc fellows, @DivyaReddyMD, @mneuman96g were unable to attend #WCLC2024 but I am so proud of their work and dedication to lung cancer research.
Bassel Nazha, MD, MPH retweeted
@DrFadloKhuri presenting on global challenges to lung cancer therapy adoption at the 2024 DDHO at Sea Island GA @AUB_Lebanon @WinshipAtEmory
Bassel Nazha, MD, MPH retweeted
🔥 session w these ⭐️s at #ASCO24
👊personal brand = what people think when they think about YOU (we all have one)
👊social media is one sphere of influence but think of your Venn diagram of spheres
👊self-promotion isn’t a dirty word for women
👊be authentic
@WinshipAtEmory
Happening now at #ASCO24 Women’s Networking Center S502:
A panel discussion on “Strategic Visibility: Elevating Visibility Through Personal Branding”
Come learn from @fumikochino @DeepaRangachari @jackiebrown_MD @AnaVManana
@WomeninOnc @HemOncWomenDocs @HemOncWomenDocs
Bassel Nazha, MD, MPH retweeted
LAURA Ph 3: Osimertinib vs Placebo #ASCO24 @ASCO
➡️ mPFS: 39.1 vs 5.6 mo (HR 0.16) ‼️
➡️ 24-mo PFS: 65% vs 13% 📈
➡️ 81% received osi at progression 💊, Good!
➡️AE discontinuation**: 13% vs 5% ⚠️
Can't wait for @RamalingamMD's presentation today! 🎤 #ASCO24 @OncoAlert Data courtesy: @FordePatrick’s tweet! @OncoAlert
Bassel Nazha, MD, MPH retweeted
❗️Make sure not to miss this education session and my talk on “Recognizing, Celebrating, and Supporting #IMGs in Oncology” at #ASCO24 ❗️
Today, 10-10:15 AM
Room S102
@ASCO @OncoAlert @IMG_Oncologists
Bassel Nazha, MD, MPH retweeted
Abs#4510 #ASCO24 @ASCO Modified FOLFIRINOX for first line Rx of advanced urachal carcinoma. Doses, regimen and results👇Encouraging ORR~61%. Key takeaways 👇 @OncoAlert @urotoday
Ab#4510 @ASCO #ASCO24by #JaeLyunLee 👉tinyurl.com/2tva9uc7👉ULTIMA ph2 trial of modified FOLFIRINOX for 1L Rx of pts w/ adv urachal cancer👉encouraging outcomes w/ ORR 61.9%, mPFS 9.3 mo & mOS 26.4 mo👇#HyoJinLee @OncoAlert @urotoday @BladderCancerUS
Bassel Nazha, MD, MPH retweeted
Amazing to hear the vision for the NCI for rapid trial activation, rapid accrual, virtual CTO, innovation unit for expediting pragmatic trials, and data integration! @UCSDCancer #ASCO24 @NCIDirector
Bassel Nazha, MD, MPH retweeted
Ongoing clinical trials with radioactive targeted therapy in #ProstateCancer presented at #SoCalGU24 by @TDorffOnc
@urotoday
Bassel Nazha, MD, MPH retweeted
🌟Thanks @SpiessPhilippe @MoffittNews 👑 it took a village to put this important data set together @KyleRoseMD writing it w style and the many amazing gobal disease leaders and friends @CurtisPettaway1 @MDAndersonNews @MaartenAlbersen @virajmaster @BasselNazha @JNCI_Now
Congratulations to the very talented Jad Chahoud for leading this new reference paper on NAC in the management of N+ve penile cancer. A true global real world experience. @JadChahoud @ASCO @myESMO ncbi.nlm.nih.gov/pubmed/3836…
Bassel Nazha, MD, MPH retweeted
The schedule for the FIFA World Cup 2026 is here, and there's no better place than Atlanta for the global game. #WeAre26 #WeAreAtlanta
Bassel Nazha, MD, MPH retweeted
grateful for the support and 🧠 of @bilenma with this study and everything else!
Great clinical trial data from our @jackiebrown_MD first nectin4 ADC+vegf tki combo @WinshipAtEmory
Bassel Nazha, MD, MPH retweeted
Adjuvant pembro for 1y convincingly improved OS for RCC, @DrChoueiri. Adj nivo for 6m didn’t meet DFS endpoint, @motzermd, inconclusive HR. I’ll be using adj pembro after shared-decision with pts at high-risk for recurrence per @PavlosMsaouel
























































